Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

Brigham and Women's Hospital10 enrolled

Overview

The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term outcomes.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Heart Transplantation

Interventions

OptisonDRUG

Echocardiogram with IV contrast

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All adult subjects (ages 18 to 75) who have undergone heart transplant at Brigham and Women's Hospital Exclusion Criteria: * hemodynamic instability (e.g., systolic blood pressure \< 90 mmHg) * atrial fibrillation with rapid ventricular response (e.g., heart rate \> 120 bpm) * premature atrial or ventricular complexes of a frequency that will not allow adequate echocardiographic assessment * poor acoustic windows * inability to provide informed consent * any contraindication listed in the Optison package insert (i.e., history of an allergic reaction)

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Global and regional microvascular myocardial perfusion

Myocardial blood flow (dB/s)

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.